This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Gersl, V Articles by Machácková, J Search for Related Content PubMed PubMed Citation Articles by Gersl, V Articles by Machácková, J Social Bookmarking                   What's this?

IGF-I in experimental daunorubicin-induced cardiomyopathy in rabbits

V Gerl

Department of Pharmacology, Faculty of Medicine, Charles University, Hradec Králové

J Cerman

Department of Medical Biochemistry, Faculty of Medicine, Charles University, Hradec Králové

P uba

Center of Experimental Neurosurgery, University Hospital, Hradec Králové

Y Mazurová

Department of Histology and Embryology, Faculty of Medicine, Charles University, Hradec Králové

R Hrdina

Department of Pharmacology and Toxicology, Faculty of Pharmacy, Charles University, Hradec Králové, Czech Republic

J Macháková

Department of Pharmacology, Faculty of Medicine, Charles University, Hradec Králové

1 The occurrence of IGF-I was investigated in rabbits with experimentally daunorubicin-induced cardiomyopathy. IGF-I was measured in the heart, serum, liver and skeletal muscle.

2 A significant increase in the IGF-I was found in the left heart ventricle in daunorubicin cardiomyopathy (152.9±10.0 ng/g vs 95.1±4.2 ng/g in the control group). This site of increased IGF-I activity corresponded well with the maximum of morphological changes (dispersed cytolysis of cardiomyocytes mostly without developed subsequent interstitial myofibrosis).

3 The highest levels of IGF-I were present in right and left cardiac atrium (but without significant differences between the groups). Furthermore, in skeletal muscle, the levels of IGF-I in the daunorubicin group (839.0±142.1 ng/g) were significantly higher in comparison with the control group (482.5±83.1 ng/g).

4 The level of IGF-I in the left ventricle in the daunorubicin group (but not in the control group) was significantly higher than that in the liver. There were no correlations observed between the levels of IGF-I in the heart and in the serum.

5 The increase in IGF-I concentrations in the left heart ventricle after the administration of daunorubicin may thus reflect possible autocrine/paracrine role of IGF-I in cardiomyopathy.

Key Words: IGF-I • somatomedin C • daunorubicin • heart • cardiomyopathy • liver • serum • skeletal muscle

Human & Experimental Toxicology, Vol. 18, No. 3, 154-161 (1999)
DOI: 10.1177/096032719901800304


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				I. Klimtova, T. Simunek, Y. Mazurova, R. Hrdina, V. Gers, and M. Adamcova Comparative study of chronic toxic effects of daunorubicin and doxorubicin in rabbits Human and Experimental Toxicology, December 1, 2002; 21(12): 649 - 657. [Abstract] [PDF]